Focused On-demand Library for DNA damage-binding protein 2

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We employ our advanced, specialised process to create targeted libraries for protein-protein interfaces.

 Fig. 1. The sreening workflow of Receptor.AI

It includes extensive molecular simulations of the target alone and in complex with its most relevant partner proteins, followed by ensemble virtual screening that accounts for conformational mobility in free and bound forms. The tentative binding pockets are considered on the protein-protein interface itself and in remote allosteric locations in order to cover the whole spectrum of possible mechanisms of action.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.







Alternative names:

DDB p48 subunit; Damage-specific DNA-binding protein 2; UV-damaged DNA-binding protein 2

Alternative UPACC:

Q92466; B2R875; Q76E54; Q76E55; Q76E56; Q76E57


DNA damage-binding protein 2, also known as DDB p48 subunit, Damage-specific DNA-binding protein 2, or UV-damaged DNA-binding protein 2, plays a crucial role in DNA repair and protein ubiquitination. It is a core component of the UV-DDB complex, recognizing UV-induced DNA damage and initiating repair via the nucleotide excision repair pathway. Additionally, it functions in the DCX (DDB2-CUL4-X-box) E3 ubiquitin-protein ligase complex, facilitating the removal of histones from nucleosomes to promote DNA repair.

Therapeutic significance:

The protein's involvement in Xeroderma pigmentosum complementation group E, a disorder characterized by heightened skin cancer risk and potential neurological abnormalities due to UV sensitivity, underscores its therapeutic significance. Understanding the role of DNA damage-binding protein 2 could open doors to potential therapeutic strategies for mitigating the effects of this condition.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.